background: The frequency for virology testing for couples undergoing assisted reproductive treatment (ART) in Europe is currently under debate, with little scientific data available to support the time-frame imposed by EU legislation. The aim of this study was to determine the incidence of blood-borne viruses (BBV) in this population and to assess the likelihood of seroconversion after an initial negative screen and the possible cost saving to couples.
Introduction
Assisted reproductive technologies (ART) in the form of IVF have been practiced for more than 30 years now (Steptoe and Edwards, 1978) , with millions of children born worldwide. IVF therapy is employed following thorough investigation of subfertile couples and as a last option when other treatments have failed. The performance of viral screening on both partners prior to IVF was introduced on a voluntary basis a long time ago. Such testing of couples has now become compulsory since the European Tissues and Cells Directive (EUTCD) was transposed into law across Europe (EU Directives 2004 /23/EC, 2006 /17/EC and 2006 . When a couple present to a clinic for fertility treatment, it is important to know their viral screen status in advance of them embarking on the journey of assisted reproduction. In circumstances where the test result shows positivity for Hepatitis B, Hepatitis C or HIV, the implications are multiple. Apart from the diagnosed individuals requiring specialist therapy for their own health, antiviral treatment may be necessary prior to any reproductive treatment to reduce the risk of transmission to their partner and offspring and the possible risk of contamination of other couples attending for treatment.
The EUTCD main objectives are to ensure the quality and safety of tissues and cells for clinical use, with viral screening being required at the time of each donation (2006/17/EC). While screening of patients prior to undergoing assisted reproduction clarifies their status, it is not clear, when these initial screens are negative, how frequently they should be repeated. An ESHRE position paper published in 2007 suggested initial screening within 30 days prior to treatment and validity for 24 months if the initial test is negative (ESHRE Position Paper, 2007) . To date, the Directive has been implemented differently in different European countries. For example, patients in Ireland are screened within 30 days before each oocyte collection, even if they recently screened negative, while in Denmark, the validity of an initial negative test is 48 months (Mocanu, 2010) . A recent review (Wingfield and Cottell, 2010) explored the published literature with regard to the perceived risks of infection and cross-contamination in ART. The authors showed that when best practice ART procedures for gamete and embryo processing have been employed, cross-contamination in the ART facility or horizontal or vertical transmission to a partner or neonate has never been documented. The question of frequency of viral screening among couples attending for ART still remains.
Intrigued by the lack of scientific data to measure the risk of seroconversion and judge the ideal frequency of re-testing, we set out to assess the incidence of these blood-borne viruses (BBV) in an ART population and also to assess the risk of seroconversion in previously Hepatitis B, Hepatitis C or HIV-negative patients attending for ART at a tertiary referral academic unit in Ireland over a 12-year period (1998) (1999) (2000) (2001) (2002) (2003) (2004) (2005) (2006) (2007) (2008) (2009) . We also compared the potential financial implications associated with testing cohabitating couples attending for ART as frequently as within 30 days of each oocyte collection, after an initial negative screen, at national and European levels, based on European ART activity reported by ESHRE (De Mouzon et al., 2010) .
Materials and Methods
In 1998, our ART unit initiated a policy of compulsory viral screening for all couples within the 6 months before their first IVF/ICSI or IUI treatment and, if any material was cryopreserved, repeat screening was requested 180 days post-freezing with a view to transfer into long-term storage, once negative status was re-confirmed. The initial screening had to be performed within 6 months of procurement. The same policy was applied for all male patients undergoing oncology cryopreservation. The viral testing included as a minimum, HIV 1 and 2, Hepatitis B surface antigen, Hepatitis C antibody and, since the implementation of the directive, Hepatitis B core antibody (2008 onwards). These tests were carried out either in the National Virus Reference Laboratory, at University College Dublin (UCD), or by the Rotunda Hospital Microbiology Laboratory which is ISO 15189 accredited. We performed a retrospective analysis of data collected prospectively by the Microbiology Department in the Rotunda Hospital. For the purpose of analysing a diverse risk background, we first looked at the incidence of seropositivity in this population overall and analysed if they, or their partners, had any additional seroconverison as partners would be considered to be at a higher risk. We then looked at all patients who attended with an initial negative status for the three viruses and who had follow-up re-testing. This was considered Group 1. Groups 2 and 3 were subdivisions of Group 1 and had in common a clearly defined interval of a minimum 180 days between the initial testing and re-testing. Group 2 was cohabiting couples undergoing ART who had surplus embryos cryopreserved and who were invited to return for follow-up screening. Both individuals within these couples were screened at the same time. Group 3 examined men who were having semen cryopreserved for oncological reasons. Some of these men were married but many were single, therefore it was not routine to screen their partner until they returned to use the cryopreserved material. This latter group was included as it was a representative of the general population in terms of seroconversion risk. All tests that were deemed indeterminate or falsely positive were excluded from the analysis.
Results
Since the implementation of screening in our unit, we identified a total of 79 291 tests performed in over 12 500 patients. These patients would have been tested since 1998 and commenced treatment thereafter. To establish the incidence, we discovered that 37 individuals were diagnosed with Hepatitis B out of 12 797 individuals tested (0.28%), 96 had Hepatitis B core antibody detected out of 2891 tested (3.32%), 43 were diagnosed with Hepatitis C out of 12 762 tested (0.33%) and 1 patient was diagnosed with HIV out of 12 819 screened (0.007%). These results are illustrated in Table I . We analysed these individuals further, given that they would be considered at a higher risk of acquiring additional infections. The repeat testing showed that neither they nor their partners had any additional seroconversions.
For Hepatitis B surface antigen testing, 6801 individuals were retested. For Hepatitis B core antibody, 774 individuals were re-tested (as per implementation of the directive in 2008). For Hepatitis C antibody, 6765 individuals were retested and for HIV, 6788 had follow-up testing. The reason for the difference in numbers is that some patients had certain viruses screened for on different dates. If some of these test results fell outside the 6-month or 30-day window (depending on clinic policy at that time), further individual tests were requested. No single case of seroconversion was identified (Group 1, Table II ). The number of patients re-tested, type of test and number of repeats for each patient were also analysed. While the vast majority of patients had 3 or 4 repeat tests, in some cases up to 11 re-tests were recorded, all without a single case of seroconversion identified. The number of indeterminate or false-positive tests was identified at rates of 0.07% (18/25 472) for Hepatitis B surface antigen, 0.07% (3/3865) for Hepatitis B core antibody, 0.5% (129/25 487) for Hepatitis C antibody and 0.3% (82/25 454) for HIV 1 and 2.
The groups we analysed allowed for comparison among different populations with presumed different risks, namely oncology patients (with the risk of seroconversion being considered similar to the general population) and couples in a stable relationship (risk of seroconversion presumed to be reduced).
In patients who had frozen embryos after an initial fresh treatment (Group 2), of the 2046 individuals who returned for repeat testing (180 days) after a negative initial screen, no seroconversions were measured. Similarly, of the 555 oncology males with initial negative screens (Group 3), no seroconversions were reported at re-test after 180 days. The analysis of all initial and repeat screens showed no seroconversions following a previously negative screen (Table II) .
Cost of re-testing with each procurement
We measured that within a 2-year period, some patients in order to comply with the directive were screened up to five times. As such, we postulated that some couples, if unsuccessful, may have up to three cycles in any 12-month period. Under the current legislation in Ireland, this means three sets of screening (12 individual tests) within a 12-month period. Based on this, with the average test costing approximately E20 and the total number of cycles undertaken in Europe (De Mouzon et al., 2010) , we calculated the financial implications of the current virology screening imposed practice to be E1 444 000 for Ireland and E240 million at the European level. We also calculated national and European cost savings if repeat screens are to be performed at yearly intervals based on our findings of negligible risk of seroconversion (Table III) .
Discussion
This is the first study specifically looking at the risk of seroconversion in patients attending for ART services in a European country. One strength of our study is that the data originate from a large unit with long-standing practice of routine viral testing of all couples attending for treatment. Previous data collected from European countries show vast variations in the way the viral screening procedure is implemented across Europe (Mocanu, 2010) . As competent authorities in different member states interpret the directive differently, we set out to scientifically assess the risk of seroconversion for oncology males and couples undergoing ART and cryopreservation and who initially screened negative for the EUTCD required tests. We studied all patients who attended our services over a period of 12 years and found no seroconversions after an initial negative screen in this large ART population. We also looked at the incidence of patients who on initial screening were found seropositive for one of the viruses. Subsequent screening of these high-risk individuals showed no further seroconversion to other viruses. Furthermore, partners of seropositive individuals who would be considered as high risk showed no seroconversions. We would support the policy of a screening questionnaire being completed prior to any individual undergoing a cycle of treatment and if any behavioural risks or relevant history is identified that may warrant additional screening, that this would be carried out. Data on seroconversion from clinics with a higher incidence of BBV in their area would be useful to discussion regarding a change in the legislation. non-ART medicine involves a recipient who has never been exposed to the donated tissues or cells received for a non-reproductive purpose. The risk of infection is significantly higher in the latter group. Last but not least, good laboratory practice, advances in sample preparation and the use of high security cryostorage methods have significantly reduced the risk of cross-contamination in the laboratory (Gilling et al., 2005) . This paper brings robust scientific evidence that the risk of seroconversion in ART patients with an initial negative screen is negligible. As such, current legislation requiring screening of couples at each procurement of cells in the assisted reproductive setting is not clinically justified. From a patient perspective, being required to have viral testing unnecessarily raises both financial but also moral concerns. Is it justifiable, based on the evidence we provide in this article, for couples to undergo a procedure which requires blood sampling as well as time and financial implications? Such concerns should be considered in any future attempts to modify the current law. As practitioners, we have the moral duty to help couples and treat their infertility, a medical condition recognized by the World Health Organisation (Zegers-Hochschild et al., 2009) . However, currently a very large sum of money is directed towards unnecessary testing. Saving E160 million annually at European level could be used to fund ART cycles for couples who cannot afford such treatment. Further data are required from other clinics that have been performing viral screening for a considerable period of time. Such data could support the present results and bring about an urgent review of the legislation as it currently stands. While the optimal re-testing frequency cannot be established to date, our data suggest that repeat screening should not be required for at least a 12-month period following initial screening.
